Louis Derick Payet’s Post

DiMe’s new Integrated Evidence Plans (IEP) for Digital Health Products (DHPs) addresses our industry's most critical needs. In the recent Digital Health Industry Regulatory Needs Assessment conducted by DiMe, the top priority reported by industry leaders is to align best practices between regulatory requirements and decision-making with downstream payers and purchasers. 🤝 DiMe is partnering with Peterson Health Technology Institute (PHTI), ZS, and other industry leaders on the new Integrated Evidence Plans (IEP) for Digital Health Products (DHPs) project. This work will identify core components of an integrated evidence plan to streamline the collection of necessary evidence for all decision-makers on the path to market and optimize developers’ opportunities for commercial success. The project will promote the successful introduction of high-quality digital health innovations to the market, preventing them from failing due to uncertainty. 🔗 Learn more about the project here: https://bit.ly/3Hug6xa Alliance of Community Health Plans (ACHP) Altoida, Inc. American College of Cardiology Astellas Pharma US Brown-Lifespan Center for Digital Health Consumer Technology Association Feel Therapeutics Galen Growth | Insights You Can Trust Genentech Google Lunit Global Lura Health Mika Health NeuraLight Otsuka Pharmaceutical Companies (U.S.) Point32Health ScreenPoint Medical Takeda Center for the Evaluation of Value and Risk in Health (CEVR) University of Michigan FDA U.S. Department of Veterans Affairs Verily

The journey of hims & hers to a large degree lays to rest the question of can you scale a virtual digital health business, to which the answer is yes. The company's metrics of 40-50% quarterly revenue growth, a 2024 revenue forecast of more than $1 billion, positive EBITDA and positive free cash flow highlights a business that is both scaled and sustainable. Hims and Hers is a digital health company that generates its revenue from a combination of providing virtual health services and through the online sale of drug / OTC products, so maybe hybrid digital health company might be more appropriate. The company has some interesting learnings for the industry, and I'd love to hear others thoughts on your read into what the sector can take away from the Company: 1. D2C digital health can work: I would caveat this with can work in 'selected areas'. Hims and Hers focuses on areas where consumers actively look for solutions (sexual health, weight loss) and are willing to spend out of pocket. I also suspect this would be areas managed at the primary care level with minimal need for other specialist support. 2. Consumer convenient end-to-end model: the Company has made significant investments in both digital systems and fulfillment capabilities, essentially creating a seamless one-stop solution for patients. By controlling this process it can control the quality and cost of the service delivered. This differs to many other digital health products that need to fit into separate work-flow and treatment flow processes. 3. Go beyond just digital health: Hims & Hers combines virtual telemedicine and product sales. I don't have access to their split revenue or EBITDA results but I would be curious to see how their revenue and profit is split between the two business lines. Is this combination model of digital health with a complimentary 'something else' a model that others can follow? The Company's results come at an interesting time for the industry with investors and others questioning can a digital health business be sustainable. At the end of the day the results achieved by Hims & Hers are a positive for the overall industry. It will be even more interesting to see if the Company's success impacts others in the industry to re-think their commercial and path to market models.

🚀 **Exploring the Intersection of Digital Health and Pharma** 🌐 In today's rapidly evolving healthcare landscape, the integration of digital technologies into pharmaceutical practices is revolutionizing patient care, drug development, and industry operations. Here's a glimpse into how digital health is reshaping the pharmaceutical sector: 1️⃣ **Enhancing Patient Engagement**: Digital health tools, such as mobile apps and wearable devices, are empowering patients to actively participate in managing their health. Pharma companies are leveraging these technologies to provide personalized support, monitor patient adherence, and collect real-world data for clinical trials. 2️⃣ **Accelerating Clinical Trials**: Digital platforms and virtual trials are streamlining the drug development process, making it more efficient and cost-effective. From remote monitoring to electronic data capture, these innovations are expediting the journey from research to market, ultimately benefiting patients waiting for life-saving treatments. 3️⃣ **Precision Medicine and Big Data**: Advances in digital health are facilitating the adoption of precision medicine approaches. By analyzing vast amounts of data, including genomic information, lifestyle factors, and patient histories, pharmaceutical companies can tailor treatments to individual patients, maximizing efficacy and minimizing side effects. 4️⃣ **Telemedicine and Remote Healthcare**: The rise of telemedicine has become increasingly prominent, especially in the wake of global health crises. Pharma companies are exploring telehealth solutions to enhance patient access to healthcare services, improve medication adherence, and support remote consultations with healthcare providers. 5️⃣ **Data Security and Regulatory Compliance**: As digital health becomes more pervasive, ensuring data security and compliance with regulations such as HIPAA and GDPR is paramount. Pharma companies are investing in robust cybersecurity measures and collaborating with regulatory agencies to uphold patient privacy and maintain trust in digital healthcare solutions. 6️⃣ **Future Outlook and Collaboration Opportunities**: Looking ahead, the synergy between digital health and pharma holds immense potential for driving innovation and improving patient outcomes. Collaborations between pharmaceutical companies, tech startups, healthcare providers, and regulatory bodies will be key to harnessing the full benefits of digital health advancements. The convergence of digital technologies and pharmaceutical expertise is ushering in a new era of healthcare innovation. As stakeholders across the industry embrace these transformative changes, we have an unprecedented opportunity to shape the future of medicine and improve the lives of patients worldwide. Let's continue to explore, collaborate, and innovate in the dynamic landscape of digital health and pharma. 💡💊

I love reading about interesting and intelligent people solving major medical challenges via innovative technology. Check out what #FeelBetter is doing! Their #AI-powered solution identifies patients who are at high risk of near-term hospitalization related to polypharmacy issues, recommends changes to medication regimens and other needed clinical interventions, and comprehensively monitors progress at the individual and population health levels. If more hospitals used this approach there would be less patients who have infections, allergic reactions and post surgery complications!

Healthcare innovations revolutionize treatments, enhancing patient outcomes, and extending lives. They drive efficiency, affordability, and accessibility, making healthcare more equitable. Innovations like telemedicine, AI diagnostics, and personalized medicine transform healthcare delivery, empowering individuals to proactively manage their health. Ultimately, these advancements are vital for global well-being and progress. The global healthcare innovation market is expanding rapidly, fueled by technological advancements and increasing demand for solutions. Entrepreneurs and investors have a plethora of opportunities to capitalize on, driving further growth and transformation in the industry. https://lnkd.in/guSVdkJr #Innovation #HealthcareInnovation #AIinHealthcare #GlobalWellbeing #HealthcareTransformation #MedicalInnovations #FutureHealthInnovation #InnovationDrivenHealth #InnovationEcosystem #DesignThinking #FunctionalInnovation Innomantra

𝐋𝐢𝐚𝐭 𝐏𝐫𝐢𝐦𝐨𝐫 𝐚𝐧𝐝 𝐡𝐞𝐫 𝐭𝐞𝐚𝐦 𝐚𝐫𝐞 𝐭𝐚𝐜𝐤𝐥𝐢𝐧𝐠 𝐚 𝐦𝐚𝐣𝐨𝐫 𝐩𝐫𝐨𝐛𝐥𝐞𝐦 𝐭𝐡𝐚𝐭'𝐬 𝐜𝐨𝐬𝐭𝐢𝐧𝐠 𝐨𝐯𝐞𝐫 $𝟓𝟎𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐧𝐧𝐮𝐚𝐥𝐥𝐲 𝐢𝐧 𝐭𝐡𝐞 𝐔.𝐒., 𝐚𝐧𝐝 𝐢𝐭'𝐬 𝐦𝐨𝐬𝐭𝐥𝐲 𝐩𝐫𝐞𝐯𝐞𝐧𝐭𝐚𝐛𝐥𝐞. I recently sat down with Liat, Co-founder and CEO of FeelBetter, a Boston startup that’s creating solutions for polypharmacy, a widespread problem impacting millions of Americans. Polypharmacy is the use of multiple medications by a single individual to manage complicated health conditions. Simply put, polypharmacy causes: ✅ increased risk of bad drug interactions ✅ side effects ✅ medication errors ✅ lower adherence Before FeelBetter, Liat worked at Teva Pharmaceuticals, the largest producer of generics, as VP of Global Portfolio for Generic Medicines. During her time there, Liat saw patients struggling to juggle large bags of medications, a challenge she personally faced when dealing with her own health issues. She knew there had to be a way to use tech to help healthcare workers reduce the downsides of polypharmacy, and she searched for solutions but found nothing. But her search led to cofounder Yoram Hordan, CTO and COO of FeelBetter, and together they launched the company. 𝐋𝐢𝐚𝐭 𝐚𝐧𝐝 𝐘𝐨𝐫𝐚𝐦 𝐫𝐚𝐢𝐬𝐞𝐝 $𝟏𝟎.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐧𝐝 𝐚𝐬𝐬𝐞𝐦𝐛𝐥𝐞𝐝 𝐚 𝐭𝐞𝐚𝐦 𝐨𝐟 𝟏𝟕 𝐭𝐨 𝐛𝐮𝐢𝐥𝐝 𝐚 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐭𝐨 𝐬𝐲𝐧𝐭𝐡𝐞𝐬𝐢𝐳𝐞: 🔍 pharmacology data 🔍 health status 🔍 medical history 🔍 clinical guidelines 🔍 evidence-based medicine. FeelBetter uses AI to analyze all this data and give clinicians actionable insights to reduce negative effects of polypharmacy. FeelBetter also identifies at-risk patients and gaps in care in order to enhance well-being and outcomes. A study conducted with Mass General Brigham showed that FeelBetter could predict which patients would require hospitalization based on medication combinations, highlighting the platform's potential to impact care and outcomes. The company was started in Israel where there is comprehensive access to patient data, and it's now expanding across the US and collaborating closely with Medicare Advantage programs, Mass General, Atlantic Health, and senior care facilities nationwide. Connect with Liat Primor to learn more. And be sure to subscribe to Tribe newsletter for the full story. #innovation #management #technology

Big Pharma is absolutely crucial for the #success of digital health. Their resources, expertise, and established networks play a vital role in driving innovation and adoption. Let's take a look at few examples: 1. Johnson & Johnson: They have been investing in digital health technologies like Health Partner, a personalized coaching platform for patients with chronic conditions. It's all about improving patient outcomes through digital solutions! 2. Novartis: They've partnered with tech companies to develop digital therapeutics. For instance, their collaboration with Pear Therapeutics led to the creation of reSET, a prescription digital therapeutic that helps treat substance use disorder. It's a powerful combination of traditional medications and software-based treatments. 3. Pfizer: They're leveraging digital health to enhance clinical trials. By using wearable devices and mobile apps, they collect real-time data from patients, making the trial process more efficient and accurate. It's all about advancing medical research! 4. Roche: Roche has been at the forefront of digital health with their efforts in personalized healthcare. They have developed digital solutions that integrate diagnostics, data analytics, and therapy to provide tailored treatment options for patients. Their aim is to improve patient outcomes through precision medicine. 5. Sanofi: Sanofi is actively investing in digital health technologies to enhance patient care. They have collaborated with various tech companies to develop digital tools and platforms that support disease management, medication adherence, and remote patient monitoring. Their focus is on empowering patients and healthcare providers with innovative digital solutions. These examples highlight how Big Pharma is embracing digital health, revolutionizing healthcare, and making a positive impact on patients' lives. It's an exciting time for the industry, and these advancements are just the beginning! 😄🌍💊 #digital #digitalassets #digitalhealth #innovation #digitalhealthsolutions #healthcare #johnsonandjohnson #pfizer #novartis #roche #sanofi

While digital transformation might be inevitable for medical technology, nearly one-third of MedTech companies do not yet have a digital strategy, according to new research from the Deloitte Center for Health Solutions. By Sheryl Jacobson, US Consulting Medtech leader, Deloitte Consulting LLP. Read t https://lnkd.in/dqJvbzXQ #financialtimes #investing #financeandeconomy #capitalraising #businessandmanagement #capital #startupstrategies #biopharma #biopharmaceuticals #pharma #technology #biopharmaceuticals #biopharma #investment #innovation #innovationinhealthcare #mna #mergersandacquisitions  #biology #startup #diagnostics #diagnostictesting #medicaldevices #medicaldevice #digitisation #digitaltransformation #digitalhealth #digitalcare #vaccination #medicaldeviceinnovation #medical #healthtech #wereabletechnology #futureofhealthcare #digitalhealth #breatcancerawareness #imagingtechnologies #imaging #medtech #artificialintelligence #ai #digitaltherapeutics #digitalhealth #healthtech #sustainabilityinhealthcare #healthcareinnovation #Switzerland  #funding #investmentopportunities #investmentstrategy #investmentresearch #biotechinvesting #medtechinvesting #healthtech #deloitteinsights #deloitte Deloitte Digital Deloitte Consulting Deloitte Insights

𝐍𝐞𝐰 𝐡𝐞𝐚𝐥𝐭𝐡 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 – digital health, drug developments, AI, innovations in diagnosis and treatment – 𝐚𝐫𝐞 𝐯𝐚𝐬𝐭𝐥𝐲 𝐢𝐦𝐩𝐫𝐨𝐯𝐢𝐧𝐠 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬' 𝐥𝐢𝐯𝐞𝐬, 𝐫𝐢𝐠𝐡𝐭? 𝐍𝐨𝐭 𝐬𝐨 𝐟𝐚𝐬𝐭. 𝐀𝐜𝐫𝐨𝐬𝐬 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝, 𝟓𝟓% 𝐛𝐞𝐥𝐢𝐞𝐯𝐞 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐰𝐢𝐥𝐥 𝐡𝐚𝐯𝐞 𝐚 𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐞 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞, 𝐰𝐢𝐭𝐡 𝟔𝟑% 𝐢𝐧 𝐭𝐡𝐞 𝐔.𝐒. 𝐬𝐡𝐚𝐫𝐢𝐧𝐠 𝐭𝐡𝐚𝐭 𝐛𝐞𝐥𝐢𝐞𝐟 (see the graphic). 2024 Edelman Trust Barometer, Special Report: Trust and Health https://lnkd.in/gXNzTXpX 𝐀𝐝𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬: 𝐀𝐜𝐜𝐞𝐩𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐀𝐈 𝐇𝐞𝐚𝐥𝐭𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 (slide 12): Patient interaction – chatbot for medical inquiries I reject this innovation – 42% I embrace this innovation – 25% Drug development – antibiotic discovery I reject this innovation – 32% I embrace this innovation – 32% Medical diagnosis – identification of abnormalities I reject this innovation – 31% I embrace this innovation – 32% 𝐒𝐨 𝐰𝐡𝐨 𝐝𝐨 𝐩𝐞𝐨𝐩𝐥𝐞 𝐭𝐫𝐮𝐬𝐭? 𝐈 𝐭𝐫𝐮𝐬𝐭 “𝐦𝐞” 𝐚𝐧𝐝 𝐦𝐲 𝐏𝐂𝐏. (Slide 22) "I expect each to play a big or huge role in making sure I am as healthy as possible:" Myself – 85% My primary care provider – 79% Government – 50% My employer – 41% Business – 33% NGOs – 32% Media – 31% 𝐄𝐝𝐞𝐥𝐦𝐚𝐧 𝐨𝐟𝐟𝐞𝐫𝐬 𝟒 𝐫𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐚𝐭𝐢𝐨𝐧𝐬 (slide 34) 1) Depoliticize health 2) Fight the health information crisis 3) Leverage provider influence 4) Put me in charge of my health 𝐂𝐨𝐦𝐦𝐞𝐧𝐭𝐚𝐫𝐲: There’s great wisdom in recommendations 3 and 4 for any companies seeking to “disrupt” existing healthcare providers, e.g., digital health startups, Big Tech, Big Retail. Patients will tend to distrust you! “Disruption” is a long and likely unproductive slog. There’s also great wisdom for care providers, especially for PCPs. “You are trusted, but don’t take it for granted. Use that trust to empower patients.” One final grain of salt -- the wording of the question leads the respondent: "I believe technology will have a negative impact..." Better wording would have been "Do you believe that tech will have a negative or positive impact...?" #AI #Trust #DigitalHealth The Fast Future Executive

Life Sciences organizations expect more than one─fifth of revenue to come from connected health in the next five years https://lnkd.in/d2ZW3XXk At last 63 per cent of life sciences organizations, across biopharma and medtech, have connected health products already on the market or under development. Irrespective of their stage of product development, life Published by https://www.pharmabiz.com/